# Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

> **NCT05003700** · PHASE2 · COMPLETED · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 39 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **DRUG:** Lenvatinib
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05003700
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-12
- **Primary completion:** 2023-05-26
- **Final completion:** 2024-07-04
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05003700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05003700, "Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05003700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*